Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: Results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Lai, Yong Rong ^a   Chen, Yu Hong ^b   Hu, Deng Ming ^c   Jiang, Ming ^d   Liu, Qi Fa ^e   Liu, Lin ^f   Hou, Jian ^g   Schwarzenberger, Paul ^h   Li, Qiao Chuan ^a   Zhang, Zhong Ming ^a   Liu, Kai Yan ^b   Huang, Xiao Jun ^b,i  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c KUNMING GENERAL HOSPITAL   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f CHONGQING MEDICAL UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h UNIVERSITY OF SOUTH ALABAMA   (United States)

ⁱ Tsinghua University   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation (allo HSCT); Graft versus host disease (GVHD) prophylaxis; Mycophenolate mofetil (MMF)

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; CYCLOSPORIN; DRUG COMBINATION; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHINESE; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NON RELAPSE MORTALITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SURVIVAL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG COMBINATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPLAN MEIER METHOD; LEUKEMIA; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DRUG COMBINATIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84906928918     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0059-3     Document Type: Article

References (40)

1. http://www.cibmtr.org Pasquini MC, Wang Z: Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at:.
2. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. WI Bensinger, PJ Martin, B Storer, R Clift, SJ Forman, R Negrin, A Kashyap, ME Flowers, K Lilleby, TR Chauncey, R Storb, FR Appelbaum, N Engl J Med 2001 344 3 175 181 10.1056/NEJM200101183440303 11172139
3. Canadian Bone Marrow Transplant Group. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. S Couban, DR Simpson, MJ Barnett, C Bredeson, L Hubesch, K Howson-Jan, TB Shore, IR Walker, P Browett, HA Messner, T Panzarella, JH Lipton, Blood 2002 100 5 1525 1531 10.1182/blood-2002-01-0048 12176866
4. European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. N Schmitz, M Beksac, D Hasenclever, A Bacigalupo, T Ruutu, A Nagler, E Gluckman, N Russell, JF Apperley, NC Gorin, J Szer, K Bradstock, A Buzyn, P Clark, K Borkett, A Gratwohl, Blood 2002 100 3 761 767 10.1182/blood-2001-12-0304 12130483
5. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. TE Tanimoto, T Yamaguchi, Y Tanaka, A Saito, K Tajima, T Karasuno, M Kasai, K Kishi, T Mori, N Maseki, S Morishima, S Miyakoshi, M Kasai, Y Ohno, SW Kim, A Numata, M Kami, Y Takaue, S Mori, M Harada, Br J Haematol 2004 125 4 480 493 10.1111/j.1365-2141.2004.04943.x 15142119
6. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005 23 22 5074 5087 10.1200/JCO.2005.09.020
7. Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia. QF Liu, J Sun, Y Zhang, XL Liu, D Xu, B Xu, R Feng, FY Meng, SY Zhou, Ai Zheng 2004 23 4 426 429 15087032
8. HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases. Y He, SZ Feng, M Wang, JL Wei, TJ Qin, Z Zhou, WJ Zhai, LG Qiu, MZ Han, Zhonghua Xue Ye Xue Za Zhi 2005 26 7 389 392 16251016
9. Allogeneic bone marrow transplantation for chronic myeloid leukemia: 118 cases analysis. D Liu, N Guo, Y Zhang, Zhonghua Xue Ye Xue Za Zhi 1999 20 8 424 426 11721424
10. T-cell depletion of HLA-identical transplants in leukemia. AM Marmont, MM Horowitz, RP Gale, K Sobocinski, RC Ash, DW van Bekkum, RE Champlin, KA Dicke, JM Goldman, RA Good, RH Herzig, R Hong, T Masaoka, AA Rimm, O Ringdh, B Speck, RS Weiner, MM Bortin, Blood 1991 78 8 2120 2130 1912589
11. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. A Urbano-Ispizua, C Rozman, C Martínez, P Marín, J Briones, M Rovira, P Féliz, MC Viguria, A Merino, J Sierra, R Mazzara, E Carreras, E Montserrat, Blood 1997 89 11 3967 3973 9166834
12. Unrelated donor marrow transplantation trial. effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. JE Wagner, JS Thompson, SL Carter, NA Kernan, Lancet 2005 366 9487 733 741 10.1016/S0140-6736(05)66996-6 16125590
13. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? R Storb, JH Antin, C Cutler, Biol Blood Marrow Transplant 2010 16 1 Suppl 18 27 10.1016/j.bbmt.2009.10.016 19857584
14. Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Y Lai, J Ma, P Schwarzenberger, W Li, Z Cai, J Zhou, Z Peng, J Yang, L Luo, J Luo, D Deng, Q Li, Y Zhou, J Liang, Bone Marrow Transplant 2009 43 1 61 67 10.1038/bmt.2008.265 18724395
15. Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. XS Zhao, Y Chen, XY Zhao, DH Liu, LP Xu, Y Wang, W Han, YH Chen, H Chen, XH Zhang, KY Liu, XJ Huang, Clin Transplant 2013 27 6 844 851 10.1111/ctr.12225 23992032
16. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. H Glucksberg, R Storb, A Fefer, CD Buckner, PE Neiman, RA Clift, KG Lerner, ED Thomas, Transplantation 1974 18 4 295 304 10.1097/00007890-197410000-00001 4153799
17. Thomas ED.1994 consensus conference on acute GVHD grading. D Przepiorka, D Weisdorf, P Martin, HG Klingemann, P Beatty, J Hows, Bone Marrow Transplant 1995 15 6 825 828 7581076
18. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. TA Gooley, W Leisenring, J Crowley, BE Storer, Stat Med 1999 18 6 695 706 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O 10204198
19. The biology of graft-versus-host reactions. RE Billingham, Harvey Lect 1966-1967 62 21 78
20. Progress and prospects: graft-versus-host disease. S Mastaglio, MT Stanghellini, C Bordignon, A Bondanza, F Ciceri, C Bonini, Gene Ther 2010 17 11 1309 1317 10.1038/gt.2010.83 20508597
21. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. T Hahn, PL McCarthy Jr, MJ Zhang, D Wang, M Arora, H Frangoul, RP Gale, GA Hale, J Horan, L Isola, RT Maziarz, JJ van Rood, V Gupta, J Halter, V Reddy, P Tiberghien, M Litzow, C Anasetti, S Pavletic, O Ringdén, J Clin Oncol 2008 26 35 5728 5734 10.1200/JCO.2008.17.6545 18981462
22. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. SM Devine, S Carter, RJ Soiffer, MC Pasquini, PN Hari, A Stein, HM Lazarus, C Linker, EA Stadtmauer, EP Alyea 3rd, CA Keever-Taylor, RJ O'Reilly, Biol Blood Marrow Transplant 2011 17 9 1343 1351 10.1016/j.bbmt.2011.02.002 21320619
23. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. R Rodriguez, R Nakamura, JM Palmer, P Parker, S Shayani, A Nademanee, D Snyder, V Pullarkat, N Kogut, J Rosenthal, E Smith, C Karanes, M O'Donnell, AY Krishnan, D Senitzer, SJ Forman, Blood 2010 115 5 1098 1105 10.1182/blood-2009-03-207563 19965688
24. A comparison of the therapeutic effects between related donor and unrelated donor allogeneic hematopoietic stem cell transplantation in treatment of leukemia. K Yang, QF Liu, ZP Fan, J Sun, D Xu, YQ Wei, Y Zhang, FY Meng, Zhonghua Nei Ke Za Zhi. 2007 46 2 135 139 [Chinese] 17445441
25. Acute Leukaemia working party of the European Group for Blood and Marrow Transplantation. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. O Ringdén, M Labopin, NC Gorin, L Volin, GF Torelli, M Attal, JP Jouet, N Milpied, G Socié C Cordonnier, M Michallet, AI Atienza, O Hermine, M Mohty, Br J Haematol 2012 157 2 220 229 10.1111/j.1365-2141.2012.09034.x 22299728
26. Risk factors for acute graft-versus-host disease. RP Gale, MM Bortin, DW van Bekkum, JC Biggs, KA Dicke, E Gluckman, RA Good, RG Hoffmann, HE Kay, JH Kersey, A Marmont, T Masaokal, AA Rimml, JJ van Rood, FE Zwaan, Br J Haematol. 1987 67 4 397 406 10.1111/j.1365-2141.1987.tb06160.x 3322360
27. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. D Weisdorf, R Hakke, B Blazar, W Miller, P McGlave, N Ramsay, J Kersey, A Filipovich, Transplantation 1991 51 6 1197 1203 10.1097/00007890-199106000-00010 2048196
28. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. RA Nash, MS Pepe, R Storb, G Longton, M Pettinger, C Anasetti, FR Appelbaum, RA Bowden, HJ Deeg, K Doney, PJ Martin, KM Sullivan, J Sanders, RP Witherspoon, Blood 1992 80 7 1838 1845 1391947
29. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. MD Eisner, CS August, Bone Marrow Transplant 1995 15 5 663 668 7670393
30. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. C Anasetti, PG Beatty, R Storb, PJ Martin, M Mori, JE Sanders, ED Thomas, JA Hansen, Hum Immunol 1990 29 2 79 91 10.1016/0198-8859(90)90071-V 2249952
31. Marrow transplantation from related donors other than HLA-identical siblings. PG Beatty, RA Clift, EM Mickelson, BB Nisperos, N Flournoy, PJ Martin, JE Sanders, P Stewart, CD Buckner, R Storb, ED Thomas, JA Hansen, N Engl J Med 1985 313 13 765 771 10.1056/NEJM198509263131301 3897863
32. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. SJ Lee, J Klein, M Haagenson, LA Baxter-Lowe, DL Confer, M Eapen, M Fernandez-Vina, N Flomenberg, M Horowitz, CK Hurley, H Noreen, M Oudshoorn, E Petersdorf, M Setterholm, S Spellman, D Weisdorf, TM Williams, C Anasetti, Blood 2007 110 13 4576 4583 10.1182/blood-2007-06-097386 17785583
33. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. ME Flowers, Y Inamoto, PA Carpenter, SJ Lee, HP Kiem, EW Petersdorf, SE Pereira, RA Nash, M Mielcarek, ML Fero, EH Warren, JE Sanders, RF Storb, FR Appelbaum, BE Storer, PJ Martin, Blood 2011 117 11 3214 3219 10.1182/blood-2010-08-302109 21263156
34. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. C Kollman, CW Howe, C Anasetti, JH Antin, SM Davies, AH Filipovich, J Hegland, N Kamani, NA Kernan, R King, V Ratanatharathorn, D Weisdorf, DL Confer, Blood 2001 98 7 2043 2051 10.1182/blood.V98.7.2043 11567988
35. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. YS Chae, SK Sohn, JG Kim, YY Cho, JH Moon, HJ Shin, JS Chung, GJ Cho, DH Yang, JJ Lee, YK Kim, HJ Kim, Bone Marrow Transplant 2007 40 6 541 547 10.1038/sj.bmt.1705770 17637692
36. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. JH Lee, YD Joo, H Kim, HM Ryoo, MK Kim, GW Lee, JH Lee, WS Lee, JH Park, SH Bae, MS Hyun, DY Kim, SD Kim, YJ Min, KH Lee, J Clin Oncol 2013 31 6 701 709 10.1200/JCO.2011.40.2362 23129746
37. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. H Liu, X Zhai, Z Song, J Sun, Y Xiao, D Nie, Y Zhang, F Huang, H Zhou, Z Fan, S Tu, Y Li, X Guo, G Yu, Q Liu, J Hematol Oncol 2013 6 15 10.1186/1756-8722-6-15 23394705
38. Graft-versus-leukemia reactions after bone marrow transplantation. MM Horowitz, RP Gale, PM Sondel, JM Goldman, J Kersey, HJ Kolb, AA Rimm, O Ringdén, C Rozman, B Speck, RL Truitt, FE Zwaan, MM Bortin, Blood 1990 75 3 555 562 2297567
39. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ: Who is the best donor for a related HLA- haplotype-mismatched transplant? Blood. 2014 Jun 10. pii: blood-2014-03-563130. [Epub ahead of print].
40. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. D Weisdorf, MJ Zhang, M Arora, MM Horowitz, JD Rizzo, M Eapen, Biol Blood Marrow Transplant 2012 18 11 1727 1733 10.1016/j.bbmt.2012.06.014 22766220